Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 3/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP7 | P09237 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | MMP12 | P39900 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.40 |
| ▸ | MME | P08473 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10583276 | 1.00 | ECE1 (0.40) | ECE1MMP2MMP7MMP9MMP12 | |
| SCHEMBL30781109 | 1.00 | ECE1 (0.40) | ECE1MMP2MMP7MMP9MMP12 | |
| SCHEMBL28183041 | 1.00 | ECE1 (0.40) | ECE1MMP2MMP7MMP9MMP12 | |
| SCHEMBL30781191 | 1.00 | ECE1 (0.40) | ECE1MMP2MMP7MMP9MMP12 | |
| SCHEMBL29367112 | 0.98 | NPY1R (0.40) | ECE1MMP2MMP7MMP9MMP12 | |
| SCHEMBL29367110 | 0.98 | NPY1R (0.40) | ECE1MMP2MMP7MMP9MMP12 | |
| SCHEMBL29936688 | 0.95 | NPY1R (0.43) | MMELTA4H | |
| SCHEMBL29937027 | 0.95 | NPY1R (0.43) | MMELTA4H | |
| SCHEMBL29757021 | 0.94 | MME (0.42) | MMELTA4H | |
| SCHEMBL28101251 | 0.93 | BACE1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4659591-A1 | TASTE-ENHANCING COMPOSITION, METHOD FOR PRODUCING SAME, FOOD PRODUCT, AND METHOD FOR ENHANCING TASTE OF FOOD PRODUCT | House Foods Group Inc. (JP) | 2025-12-10 | — | — | EP | claimed |
| US-20240342252-A1 | PROCESS OF MAKING ABALOPARATIDE | RADIUS HEALTH, INC. (US) | 2024-10-17 | — | — | US | claimed |
| WO-2024162422-A1 | TASTE-ENHANCING COMPOSITION, METHOD FOR PRODUCING SAME, FOOD PRODUCT, AND METHOD FOR ENHANCING TASTE OF FOOD PRODUCT | ハウス食品グループ本社株式会社 | 2024-08-08 | — | — | WO | claimed |
| CN-118048369-A | Dipsacus asperoides CYP450 type DaCYP085 monooxygenase gene and application thereof | 云南农业大学 | 2024-05-17 | — | — | CN | claimed |
| CN-114908114-B | Yeast cell gene modification method, recombinant yeast and application thereof | 深圳大学 | 2024-03-12 | — | — | CN | claimed |
| CN-117624291-A | Uric acid-reducing tetrapeptide with hypoxanthine binding capacity, and encoding gene and application thereof | 华南理工大学 | 2024-03-01 | — | — | CN | claimed |
| CN-114853677-B | Preparation method of leucyl histidine | 湖北泓肽生物科技有限公司 | 2023-11-14 | — | — | CN | claimed |
| CN-116948008-A | Preparation method of salmon calcitonin | 上海苏豪逸明制药有限公司 | 2023-10-27 | — | — | CN | claimed |
| CN-115047120-A | Dansyl chloride derivatization method for analyzing and detecting dipeptide substances in white spirit Daqu | 贵州茅台酒股份有限公司 | 2022-09-13 | — | — | CN | claimed |
| CN-114908114-A | Yeast cell gene modification method, recombinant yeast and application thereof | 深圳大学 | 2022-08-16 | — | — | CN | claimed |
| CN-114853677-A | Preparation method of leucyl histidine | 湖北泓肽生物科技有限公司 | 2022-08-05 | — | — | CN | claimed |
| CN-113967247-A | Blood pressure reducing pill and preparation method thereof | 柳春曦 | 2022-01-25 | — | — | CN | claimed |
| WO-2026089754-A1 | COMPOSITIONS AND METHODS FOR INTRANASAL DELIVERY OF THERAPEUTIC PEPTIDES | Finitus, LLC (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2026089752-A1 | COMPOSITIONS AND METHODS FOR MICROSPHERE DELIVERY OF THERAPEUTIC PEPTIDES | Finitus, LLC (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260108467-A1 | COMPOSITIONS AND METHODS FOR MICROSPHERE DELIVERY OF THERAPEUTIC PEPTIDES | FINITUS LLC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260108583-A1 | COMPOSITIONS AND METHODS FOR INTRANASAL DELIVERY OF THERAPEUTIC PEPTIDES | FINITUS LLC (US) | 2026-04-23 | — | — | US | disclosed |
| WO-2013086365-A2 | BIOMARKERS FOR KIDNEY CANCER AND METHODS USING THE SAME | METABOLON, INC. (US) | 2013-06-13 | — | — | WO | disclosed |
| EP-0312124-A2 | Process for the preparation of optically-active cyanomethyl esters | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-04-19 | — | — | EP | disclosed |
| EP-0291626-A2 | Process for the preparation of optically-active cyanomethyl esters | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-11-23 | — | — | EP | disclosed |
| EP-0116914-A1 | Preparation of optically-active alpha-substituted carboxylic esters and acids | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108583-A1 | COMPOSITIONS AND METHODS FOR INTRANASAL DELIVERY OF THERAPEUTIC PEPTIDES | MUC1, VIP, LGALS4 | ECE1 2597/4885MMP2 84/4885MMP7 626/4885 |
| US-20260108467-A1 | COMPOSITIONS AND METHODS FOR MICROSPHERE DELIVERY OF THERAPEUTIC PEPTIDES | FGF23, FIBP, PTMS | ECE1 3158/4885MMP2 1868/4885MMP7 670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.